Systemic sclerosis (scleroderma): open trials in Romania

3 open trials have a site in Romania. Registry data; only the trial team decides who can take part.

NCT06991114
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Trial Treatment · Phase 2 · Artiva Biotherapeutics, Inc.
Artiva Investigational Site Bucuresti, Bucharest · Artiva Investigational Site Bucharest, Bucharest
Registry updated 2026-07-31
NCT07115745
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Trial Treatment · Phase 1 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Institutul Clinic Fundeni, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca
Registry updated 2026-07-14
NCT07348263
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Research · Meyer Children's Hospital IRCCS
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca
Registry updated 2026-03-11

This page is not medical advice. Talk to your doctor before contacting a trial.

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.